Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 22;12(3):329.
doi: 10.3390/jpm12030329.

The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios

Ciro Manzo  1 , Elvis Hysa  2 , Alberto Castagna  3 , Marco Isetta  4
Affiliations

The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios

Ciro Manzo et al. J Pers Med. .

Abstract

Background: Glucocorticoids (GCs) are the cornerstone of polymyalgia rheumatica (PMR) therapy, but their long-term use (as is usually necessary in PMR patients) can induce many adverse events. Alternatives have long been sought. The primary aim of our narrative review is to provide an overview about the use of anti-tumor necrosis factor alpha (TNF-α) drugs in patients with PMR, and discuss advantages and disadvantages.

Materials and methods: we performed a non-systematic literature search (PRISMA protocol not followed) on PubMed and Medline (OVID interface).

Results and conclusions: only two anti TNF-α drugs have been prescribed to PMR patients: infliximab in 62 patients and etanercept in 28 patients. These drugs were normally used in addition to GCs when significant comorbidities and/or relapsing PMR were present; less commonly, they were used as first-line therapy. In general, they have been scarcely successful in patients with PMR. Indeed, randomized controlled trials did not confirm the positive results reported in case reports and/or case series. However, an administration schedule and study design different from those proposed in the past could favour new scenarios in the interest of PMR patients.

Keywords: anti TNF-a; etanercept; infliximab; interleukin-6; nnarrative review; polymyalgia rheumatica; tumor necrosis factor alfa.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Raheel S., Shbeeb I., Crowson C.A., Matteson E.L. Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: A population-based study. Arthritis Care Res. 2017;69:1282–1285. doi: 10.1002/acr.23132. - DOI - PMC - PubMed
    1. Cimmino M.A., Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin. Exp. Rheumatol. 2000;18:S9–S11. - PubMed
    1. Manzo C. Incidence and prevalence of Polymyalgia Rheumatica (PMR): The importance of the epidemiological context. The Italian case. Med. Sci. 2019;7:92. doi: 10.3390/medsci7090092. - DOI - PMC - PubMed
    1. Sharma A., Mohammad A.J., Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. Semin. Arthritis Rheum. 2020;50:1040–1048. doi: 10.1016/j.semarthrit.2020.07.005. - DOI - PubMed
    1. Rooney P.J., Rooney J., Balint G., Balint P. Polymyalgia rheumatica: 125 years of epidemiological progress? Scott. Med. J. 2015;60:50–57. doi: 10.1177/0036933014551115. - DOI - PubMed

LinkOut - more resources